OptimizeRx (NASDAQ:OPRX) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS

OptimizeRx (NASDAQ:OPRX) announced its quarterly earnings data on Wednesday. The company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05, FiscalAI reports. OptimizeRx had a net margin of 4.66% and a return on equity of 9.52%. The firm had revenue of $20.50 million during the quarter, compared to the consensus estimate of $20.20 million.

Here are the key takeaways from OptimizeRx’s conference call:

• Q2 revenue fell 30% year over year to $20.5 million, while adjusted EBITDA declined to $4.9 million; management attributed the weakness to a few large customers, lower-margin managed services roll-off, macroeconomic pressures, and MFN-related spending caution.
• OptimizeRx reiterated full-year 2026 guidance for revenue of $95 million-$100 million and adjusted EBITDA of $21 million-$25 million, with revenue expected to be heavily weighted toward the second half and Q4 representing 35%-40% of annual revenue.
• Margin performance and cash generation improved despite lower revenue: gross margins are now expected to normalize in the high-60% to low-70% range, first-half operating cash flow was $8.1 million, and debt was reduced to $19.7 million at quarter-end, with an additional $3 million paid down afterward.
• The company reported growing adoption of its AI-enabled offerings, including Dynamic Audience Activation, which increased more than 30% year over year, and AI software revenue, which rose 25%; new launches include DeepIntent programmatic integration, the Natural Language Audience Builder, and CopayCue.
• DeepIntent integration is now live and generating bid flow, potentially expanding access to programmatic healthcare advertising budgets, while management also announced that Andy D’Silva will become CFO on January 1, 2027, succeeding Edward Stelmakh after a planned transition.

OptimizeRx Price Performance

OPRX opened at $8.78 on Friday. The company has a 50 day moving average of $6.04 and a two-hundred day moving average of $6.72. The company has a quick ratio of 5.37, a current ratio of 5.37 and a debt-to-equity ratio of 0.16. OptimizeRx has a 52-week low of $4.54 and a 52-week high of $22.25. The company has a market cap of $164.71 million, a P/E ratio of 38.18 and a beta of 1.08.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of OptimizeRx in a research note on Tuesday. Zacks Research downgraded OptimizeRx from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 4th. Lake Street Capital cut their price objective on shares of OptimizeRx from $20.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Citigroup reissued a “market outperform” rating on shares of OptimizeRx in a research note on Friday. Finally, Stifel Nicolaus set a $12.00 target price on shares of OptimizeRx in a research report on Thursday. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $13.29.

Hedge Funds Weigh In On OptimizeRx

A number of institutional investors and hedge funds have recently bought and sold shares of OPRX. Barclays PLC grew its stake in shares of OptimizeRx by 18.7% during the fourth quarter. Barclays PLC now owns 27,441 shares of the company’s stock valued at $336,000 after acquiring an additional 4,317 shares in the last quarter. GWN Securities Inc. acquired a new stake in OptimizeRx during the fourth quarter valued at approximately $274,000. Worth Venture Partners LLC bought a new position in OptimizeRx during the 3rd quarter worth approximately $220,000. Creative Planning acquired a new position in shares of OptimizeRx in the 3rd quarter worth approximately $331,000. Finally, Massar Capital Management LP acquired a new stake in shares of OptimizeRx during the 2nd quarter valued at approximately $297,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.